2018
Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions
Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.Peer-Reviewed Original ResearchRBC transfusion independenceHMA initiationTransfusion independenceTransfusion dependenceLR-MDSClinical trial dataHypomethylating agentTransfusion statusMedian timeMedian TI durationCox modelContinuous Medicare Parts ATrial dataRed blood cell transfusionDiagnosis of MDSRBC transfusion dependenceSubset of ptsBlood cell transfusionEnd Results-MedicareErythropoiesis-stimulating agentsHigh-risk diseaseMultivariate Cox modelTreatment of MDSEnd of studyTI duration
2015
Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)
Ma X, Swern A, Kiselev P, Fliss A, Lu J, Scott B, Steensma D, Sugrue M. Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS). Blood 2015, 126: 3319. DOI: 10.1182/blood.v126.23.3319.3319.Peer-Reviewed Original ResearchDiagnosis of MDSICD-9-CM codesReal-world cohortMyelodysplastic syndromeActive treatmentEMR databaseFinal cohortInitial cohortCelgene CorporationBaseline characteristicsSupportive careSupportive treatmentTreatment patternsClinical trialsSEER programInclusion criteriaReal-world clinical practiceElectronic medical record databaseClinical Modification codesPopulation-based surveillanceEnd Results ProgramPrimary care physiciansCancer outcomes researchBone marrow aspirateClinical practice data